DaVita Inc. Schedules 2nd Quarter 2011 Investor Conference Call

DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with end stage renal disease (ESRD) and chronic kidney disease (CKD), announced today that it will hold its quarterly conference call to discuss second quarter results on Wednesday, Aug. 3, 2011 at 5:00 p.m. Eastern Time. The company plans to release its results at market close the same day.

This call is also being webcast and can be accessed at the DaVita IR web page or over CCBN’s Investor Distribution Network. You can join this call on:

Wednesday, Aug. 3, 2011 
Starting at 5:00 p.m. EDT
Dial in Number: 800-399-4406
Webcast: www.davita.com or www.fulldisclosure.com

When calling in, please refer to the “DaVita Q2 2011” call and provide the operator with your name and company affiliation. Investors who are unable to listen to the DaVita earnings conference call will be able to access a replay via our website at www.davita.com. There will be no telephone replay.

About DaVita

DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services and education to patients with chronic kidney failure and end stage renal disease. As of March 31, 2011, DaVita operated or provided administrative services at 1,642 dialysis facilities, serving approximately 128,000 patients. DaVita develops, participates in and donates to numerous programs dedicated to transforming communities and creating positive, sustainable change for children, families and our environment. The company’s leadership development initiatives and corporate social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu, among others. For more information, please visit www.davita.com.

Contacts:

Investor Contact Information:
DaVita Inc.
Jim Gustafson
310-536-2585
Jim.gustafson@davita.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.